Following an 18-month-long investigation by the United States Senate Committee on Finance, Gilead’s pricing and marketing strategy for its hepatitis drugs, Sovaldi and Harvoni, was deemed one that chooses profit over patient access. In order to appropriately shape policy related to these findings, the Committee has written a letter to the healthcare and patient […]
Posts Tagged ‘Gilead’